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Abstract
Goal of surgery for patients with Glioblastoma
Multiforme (GBM) is gross total resection with no new
neurological deficits. Surgical resection is often restricted
due the difficulty in differentiating the tumour from
surrounding normal brain using either naked eye, or
standard intra-operative white light microscopy. GBM
uptakes orally administered 5-ALA becomes fluorescent
when viewed by a special light, and this property has
been used to improve intra-operative tumour
identification. This technique should therefore allow
better extent of tumour resection. The hypothesis has
been tested through several studies and even though
most studies are of low quality, they strongly favour the
use of 5- ALA in improving the extent of resection when
compared to white light microscopy. A systematic review
on the topic had a similar conclusion. Few studies have
also hinted on a high false negative rate with the use of
this technique. 
Keywords: Glioblastoma, 5-ALA, Extent of Resection,
Overall Survival.
Introduction
Glioblastoma Multiforme (GBM) is a malignant brain
tumour of glial origin that carries a poor prognosis.
Despite all the surgical and medical advancement in the
treatment of GBM, median survival has not exceeded 15
months, although survival may range between 3 months
to 2 years.1 In some cases of secondary GBM, survival has
also been reported for up to 10 years.2 Surgical approach
aimed at gross total resection enhances the efficacy of
adjuvant treatment and prolongs the survival in such
patients.3 Nearly 80% of recurrence develop within 2cm
of the resection margin.3 Various modalities have been
tried in order to improve extent of tumour resection,
including neuronavigation, intra-operative ultrasound,
intra-operative MRI (iMRI), awake craniotomy and more
recently, 5-aminolevulinic acid (5-ALA) fluorescence
guidance. 
5-ALA was approved by the European Medicines
Agency (EMA) in 2007, although Food and Drug
Administration (FDA) is yet to approve it. It is a
biochemical precursor for the heme group and its oral
administration leads to its accumulation in
glioblastoma cells causing florescence under modified
microscopy.4 This florescence helps the visualization of
GBM by the operating surgeon, and its differentiation
from normal brain tissue. In this review we look at the
use of 5-ALA in procedures aimed at complete
resection and effects on improvement in survival
compared to conventional surgeries.
Review of Evidence
We searched PubMed database for articles assessing
the use of 5-ALA in enhancing extent of resection for
GBM. No limit was set on the date of publication and
the review was completed in December 2016. Stummer
et al., in his landmark paper published in 2006 reported
the first phase III trial for 5-ALA and reported complete
tumour resection in 65% patients when 5-ALA assisted
margin identification was used, compared with 36% in
patients undergoing conventional resection.5 They
interpreted that significantly better intra-operative
tumour identification, and tumour resection was
achieved using 5-ALA fluorescence guidance,
especially in contrast enhancing tumours. Six months
progression free survival in 5-ALA assisted procedures
was reported at 41.0% compared to 21.1% with
conventional procedures (p=0.0003).5 In 2008,
Stummer et al., also reported that complete resection
using intra-operative 5-ALA significantly prolonged
survival in patients with GBM.6
Another multicenter, prospective observational study
reported complete resection in 54% of patients with
GBM when 5-ALA was used, even though the surgeons
found the fluorescence to be suboptimal in 40% of the
surgeries. They also observed that complete resection
was not affected by patients' characteristics such as
age, gender, care center, comorbidities, location or
histological grade of the tumour. Their mean
progression free survival was 6.9 months, while the
overall survival was 14.2 months. The overall or
J Pak Med Assoc
1630
EVIDENCE BASED NEURO-ONCOLOGY
Role of 5-ALA in improving extent of tumour resection in patients with
Glioblastoma Multiforme
Muhammad Waqas, Inamullah Khan, Muhammad Shahzad Shamim
Aga Khan University Hospital, Karachi, Pakistan.
Correspondence:Muhammad Shahzad Shamim.
Email: shahzad.shamim@aku.edu
progression free survival had no statistically significant
association with the extent of resection.7
A 2014 study reported the comparison between extent of
resection with the help of 5-ALA and neuronavigation
guidance. Although 98% tumour resection was achieved
in 90% patients, in 43% patients fluorescent defined
margins of tumour exceeded the margins identified by
neuronavigation leading to more complete resection. The
difference in borders was more frequent in recurrent
(60%) and larger (57%) tumours. These findings clearly
establish the superiority of 5-ALA over standard
neuronavigation.8
Another paper in 2015 combined 5-ALA guidance with
iMRI to explore further improvement in extent of
resection. The fluorescence correctly identified tumour
presence in 96% of the cases, although lack of
fluorescence correctly identified the absence of tumour in
only 12.5% of the cases. They concluded that addition of
iMRI might even further improve extent of resection over
using 5-ALA alone.9
Other papers have also reported better extent of
resection for GBM patients with 5-ALA guidance, which
also improves progression free survival.10 However, the
evidence to support improvements in overall survival,
remains inconclusive.11
Regarding safety and adverse effects with the use of 5-
ALA, no study reports significant side effects with the
therapy. Photosensitivity, a feared side effect is not
mentioned by any of the studies, keeping in mind a
controlled environment with no direct sunlight and a low
lit room environment in the first 24 hours post
procedure.12 An insignificant increase in liver enzymes is
reported in the first month post-surgery, but the levels
subsequently return to normal. Mild leukocytosis,
anaemia and thrombocytopenia may also be noticed with
spontaneous recovery.6 Cost however remains a major
concern with 5-ALA use.
Conclusion
Most of the studies strongly favour the use of 5- ALA in
improving the extent of resection when compared to
white light intra-operative microscopy. A few studies have
also suggested a high false negative rate with the use of
this technique. 
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Figure-1: a, b) MRI T1WI pre and post contrast axial images showing a potentially resectable right temporal GBM.
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